At the news
? NEUTRALIMPACT 5/10 6-K filed May 14, 2026 at 08:00 ET
Chemomab Therapeutics reported Q1 2026 financial results, with net loss narrowing to $1.8M from $3.3M YoY on lower R&D spend as the Phase 2 SPRING trial winds down. Cash of $8.0M funds operations through Q1 2027. The company highlighted new biomarker data from nebokitug in PSC suggesting potential benefit in PSC patients with co-existing IBD, and continues to advance partnering discussions.
- Net loss of $1.8M in Q1 2026 vs $3.3M in Q1 2025
- Cash, cash equivalents and short-term bank deposits of $8.0M as of March 31, 2026
- Cash runway expected to fund operations through end of Q1 2027
- R&D expenses decreased to $0.9M from $2.5M YoY due to winding down of Phase 2 SPRING trial
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access